Creative Medical Technology Holdings Inc. - CELZ Total Company Value-to-Revenue Ratio

Official company branding of Creative Medical Technology Holdings Inc. (CELZ)

Creative Medical Technology is developing the AmnioStem platform by investing in the treatment of urological pathologies. The company's EV/Sales ratio visualizes the business value to sales dynamics, where the value 0.00 reflects the current magnitude. Costly cryogenic cell delivery complicates supply chains, while the absence of commercial products forces the company to rely on existing investment reserves.

Creative Medical Technology Holdings Inc. (CELZ) - EV/Sales Multiple from 11/23/2025 to 11/19/2026

CELZ (Creative Medical Technology Holdings): analytical breakdowns and indicator data

Product sample of creativemedicaltechnology.com

To assess the financial stability of Creative Medical Technology (CELZ), it is critical to analyze the enterprise value of the business, accounting for net debt relative to sales volume. This EV/Sales metric demonstrates the price of every dollar of revenue, allowing investors to compare current capitalization with the pace of patent commercialization in regenerative medicine and the expansion of the company's clinic network.